Eton Pharmaceuticals, Inc.

NasdaqGM:ETON 株式レポート

時価総額：US$149.8m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Eton Pharmaceuticals マネジメント

マネジメント 基準チェック /34

Eton Pharmaceuticals'の CEO はSean Brynjelsenで、 Jun2017年に任命され、 の在任期間は 7.08年です。 の年間総報酬は$ 1.75Mで、 33.9%給与と66.1%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の4.18%を直接所有しており、その価値は$ 3.54M 。経営陣と取締役会の平均在任期間はそれぞれ2.5年と6.8年です。

主要情報

Sean Brynjelsen

最高経営責任者

US$1.7m

報酬総額

CEO給与比率33.9%
CEO在任期間7.3yrs
CEOの所有権4.2%
経営陣の平均在職期間2.4yrs
取締役会の平均在任期間7yrs

経営陣の近況

Recent updates

After Leaping 26% Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Are Not Flying Under The Radar

Sep 10
After Leaping 26% Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Are Not Flying Under The Radar

Subdued Growth No Barrier To Eton Pharmaceuticals, Inc. (NASDAQ:ETON) With Shares Advancing 40%

Jan 09
Subdued Growth No Barrier To Eton Pharmaceuticals, Inc. (NASDAQ:ETON) With Shares Advancing 40%

The Consensus EPS Estimates For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Just Fell A Lot

Dec 13
The Consensus EPS Estimates For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Just Fell A Lot

Eton Pharmaceuticals' (NASDAQ:ETON) Earnings May Just Be The Starting Point

Nov 16
Eton Pharmaceuticals' (NASDAQ:ETON) Earnings May Just Be The Starting Point

Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Despite Losing Money

Sep 30
Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Despite Losing Money

Not Many Are Piling Into Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Yet As It Plummets 26%

Jul 25
Not Many Are Piling Into Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Yet As It Plummets 26%

Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?

Jun 29
Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?

Is Eton Pharmaceuticals (NASDAQ:ETON) Using Debt In A Risky Way?

Dec 22
Is Eton Pharmaceuticals (NASDAQ:ETON) Using Debt In A Risky Way?

Eton Pharmaceuticals acquires FDA-approved rare disease product betaine anhydrous

Sep 13

Eton Pharmaceuticals: An Evolving 'Sum Of The Parts' Story

Aug 14

Eton Pharma jumps 20% on FDA approval of seizure therapy

Jul 18

Broker Revenue Forecasts For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Are Surging Higher

Apr 15
Broker Revenue Forecasts For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Are Surging Higher

Eton Pharmaceuticals (NASDAQ:ETON) Is Using Debt Safely

Oct 14
Eton Pharmaceuticals (NASDAQ:ETON) Is Using Debt Safely

Another Look At Eton Pharmaceuticals

Sep 03

What Does The Future Hold For Eton Pharmaceuticals, Inc. (NASDAQ:ETON)? These Analysts Have Been Cutting Their Estimates

Aug 18
What Does The Future Hold For Eton Pharmaceuticals, Inc. (NASDAQ:ETON)? These Analysts Have Been Cutting Their Estimates

Eton Pharma wins FDA approval for Rezipres

Jun 15

FDA declines to approve Eton Pharmaceuticals' methanol poisoning treatment

May 28

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Is About To Turn The Corner

May 15
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Is About To Turn The Corner

Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?

Apr 05
Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?

Could The Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Ownership Structure Tell Us Something Useful?

Mar 01
Could The Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Ownership Structure Tell Us Something Useful?

Eton Pharma buys Canadian rights for Alkindi Sprinkle

Jan 14

Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Shift From Loss To Profit

Jan 07
Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Shift From Loss To Profit

CEO報酬分析

Eton Pharmaceuticals の収益と比較して、Sean Brynjelsen の報酬はどのように変化したか？
日付総報酬給与会社業績
Jun 30 2024n/an/a

-US$7m

Mar 31 2024n/an/a

US$913k

Dec 31 2023US$2mUS$592k

-US$936k

Sep 30 2023n/an/a

US$2m

Jun 30 2023n/an/a

-US$234k

Mar 31 2023n/an/a

-US$6m

Dec 31 2022US$2mUS$570k

-US$9m

Sep 30 2022n/an/a

-US$9m

Jun 30 2022n/an/a

-US$12m

Mar 31 2022n/an/a

-US$12m

Dec 31 2021US$2mUS$542k

-US$2m

Sep 30 2021n/an/a

-US$11m

Jun 30 2021n/an/a

-US$11m

Mar 31 2021n/an/a

-US$14m

Dec 31 2020US$2mUS$476k

-US$28m

Sep 30 2020n/an/a

-US$23m

Jun 30 2020n/an/a

-US$21m

Mar 31 2020n/an/a

-US$20m

Dec 31 2019US$2mUS$410k

-US$18m

Sep 30 2019n/an/a

-US$42m

Jun 30 2019n/an/a

-US$40m

Mar 31 2019n/an/a

-US$41m

Dec 31 2018US$493kUS$332k

-US$37m

Sep 30 2018n/an/a

-US$18m

Dec 31 2017US$654kUS$172k

-US$13m

報酬と市場: Seanの 総報酬 ($USD 1.75M ) は、 US市場 ($USD 666.73K ) の同規模の企業の平均を上回っています。

報酬と収益: Seanの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Sean Brynjelsen (52 yo)

7.3yrs

在職期間

US$1,747,045

報酬

Mr. Sean E. Brynjelsen has been the Chief Executive Officer at Eton Pharmaceuticals, Inc. since June 23, 2017 and serves as President and Director since June 2017. Mr. Brynjelsen served as Executive Vice P...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Sean Brynjelsen
President7.3yrsUS$1.75m4.16%
$ 6.2m
James Gruber
CFO, Treasurer & Secretary2.4yrsUS$785.14k0.049%
$ 73.1k
David Krempa
Chief Business Officer1.5yrsUS$719.08k0.081%
$ 120.6k
Danka Radosavljevic
Senior Vice President of Quality & Operationsless than a yearデータなしデータなし
Scott Grossenbach
Vice President of Sales Operationsno dataデータなしデータなし
Kevin Guthrie
Executive VP of Commercial Operations2.7yrsデータなしデータなし

2.4yrs

平均在職期間

52yo

平均年齢

経験豊富な経営陣: ETONの経営陣は 経験豊富 であると考えられます ( 2.4年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Sean Brynjelsen
President7.3yrsUS$1.75m4.16%
$ 6.2m
Paul Maier
Independent Director7yrsUS$129.50k0.23%
$ 346.5k
Charles Casamento
Independent Director7.3yrsUS$126.90k0.26%
$ 396.8k
Norbert Riedel
Independent Chairman7yrsUS$155.50k0.23%
$ 346.5k
Jennifer Adams
Independent Director3.5yrsUS$119.10kデータなし

7.0yrs

平均在職期間

66yo

平均年齢

経験豊富なボード: ETONの 取締役会 は 経験豊富 であると考えられます ( 6.8年の平均在任期間)。